Table 1: Open in new tab Preoperative...

Degenerative (N = 2530)

Secondary (N = 115)

P-value

Age, median (IQR)

57 (47–66)

68 (63–72)

<0.001

Female sex, n (%)

837 (33)

45 (39)

0.178

NYHA class I, n (%)

594 (23)

0 (0)

0.999

NYHA class II, n (%)

1475 (59)

25 (21)

<0.001

NYHA class III, n (%)

390 (15)

55 (48)

<0.001

NYHA class IV, n (%)

71 (3)

35 (31)

<0.001

REDO, n (%)

69 (2.7)

2 (1.7)

0.521

Creatinine clearance 85–50 ml/min, n (%)

91 (3.6)

7 (6)

0.166

Creatinine clearance <50 ml/min, n (%)

35 (1.4)

5 (4.3)

0.010

Dialysis regardless of the creatinine clearance, n (%)

19 (0.75)

2 (1.7)

0.242

Insulin dependent diabetes mellitus, n (%)

110 (4.3)

37 (32)

<0.001

Extracardiac arteriopathy, n (%)

27 (1)

7 (6)

<0.001

COPD, n (%)

40 (1.6)

4 (3.5)

0.119

Ejection fraction, median (IQR)

61 (58–66)

35 (30–42)

<0.001

Moderate pulmonary hypertension (SPAP 30–55 mmHg), n (%)

832 (32.8)

66 (57)

<0.001

Severe pulmonary hypertension (SPAP >55 mmHg), n (%)

220 (8)

28 (24)

<0.001

Isolated mitral valve repair, n (%)

1779 (71)

52 (45)

<0.001

Mitral valve repair + 1 procedure, n (%)

571 (22)

60 (53)

<0.001

Mitral valve repair + 2 or more procedure, n (%)

180 (7)

3 (2)

0.062

EuroSCORE II, median (IQR)

1 (0.6–1.5)

2.4 (1.5–4.1)

<0.001

Table 1:

Open in new tab

Preoperative characteristics of the patients in the 2 groups

	Degenerative (N = 2530)	Secondary (N = 115)	P-value
Age, median (IQR)	57 (47–66)	68 (63–72)	<0.001
Female sex, n (%)	837 (33)	45 (39)	0.178
NYHA class I, n (%)	594 (23)	0 (0)	0.999
NYHA class II, n (%)	1475 (59)	25 (21)	<0.001
NYHA class III, n (%)	390 (15)	55 (48)	<0.001
NYHA class IV, n (%)	71 (3)	35 (31)	<0.001
REDO, n (%)	69 (2.7)	2 (1.7)	0.521
Creatinine clearance 85–50 ml/min, n (%)	91 (3.6)	7 (6)	0.166
Creatinine clearance <50 ml/min, n (%)	35 (1.4)	5 (4.3)	0.010
Dialysis regardless of the creatinine clearance, n (%)	19 (0.75)	2 (1.7)	0.242
Insulin dependent diabetes mellitus, n (%)	110 (4.3)	37 (32)	<0.001
Extracardiac arteriopathy, n (%)	27 (1)	7 (6)	<0.001
COPD, n (%)	40 (1.6)	4 (3.5)	0.119
Ejection fraction, median (IQR)	61 (58–66)	35 (30–42)	<0.001
Moderate pulmonary hypertension (SPAP 30–55 mmHg), n (%)	832 (32.8)	66 (57)	<0.001
Severe pulmonary hypertension (SPAP >55 mmHg), n (%)	220 (8)	28 (24)	<0.001
Isolated mitral valve repair, n (%)	1779 (71)	52 (45)	<0.001
Mitral valve repair + 1 procedure, n (%)	571 (22)	60 (53)	<0.001
Mitral valve repair + 2 or more procedure, n (%)	180 (7)	3 (2)	0.062
EuroSCORE II, median (IQR)	1 (0.6–1.5)	2.4 (1.5–4.1)	<0.001

	Degenerative (N = 2530)	Secondary (N = 115)	P-value
Age, median (IQR)	57 (47–66)	68 (63–72)	<0.001
Female sex, n (%)	837 (33)	45 (39)	0.178
NYHA class I, n (%)	594 (23)	0 (0)	0.999
NYHA class II, n (%)	1475 (59)	25 (21)	<0.001
NYHA class III, n (%)	390 (15)	55 (48)	<0.001
NYHA class IV, n (%)	71 (3)	35 (31)	<0.001
REDO, n (%)	69 (2.7)	2 (1.7)	0.521
Creatinine clearance 85–50 ml/min, n (%)	91 (3.6)	7 (6)	0.166
Creatinine clearance <50 ml/min, n (%)	35 (1.4)	5 (4.3)	0.010
Dialysis regardless of the creatinine clearance, n (%)	19 (0.75)	2 (1.7)	0.242
Insulin dependent diabetes mellitus, n (%)	110 (4.3)	37 (32)	<0.001
Extracardiac arteriopathy, n (%)	27 (1)	7 (6)	<0.001
COPD, n (%)	40 (1.6)	4 (3.5)	0.119
Ejection fraction, median (IQR)	61 (58–66)	35 (30–42)	<0.001
Moderate pulmonary hypertension (SPAP 30–55 mmHg), n (%)	832 (32.8)	66 (57)	<0.001
Severe pulmonary hypertension (SPAP >55 mmHg), n (%)	220 (8)	28 (24)	<0.001
Isolated mitral valve repair, n (%)	1779 (71)	52 (45)	<0.001
Mitral valve repair + 1 procedure, n (%)	571 (22)	60 (53)	<0.001
Mitral valve repair + 2 or more procedure, n (%)	180 (7)	3 (2)	0.062
EuroSCORE II, median (IQR)	1 (0.6–1.5)	2.4 (1.5–4.1)	<0.001

IQR: interquartile range.

This Feature Is Available To Subscribers Only